Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study

被引:57
作者
Sookoian, Silvia [1 ]
Alejandra Fernandez, Maria [2 ]
Castano, Gustavo [3 ,4 ]
机构
[1] Univ Buenos Aires, Inst Invest Med A Lanari, Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Sch Pharm & Biochem, Cathedra Physiopathol, Buenos Aires, DF, Argentina
[3] Govt City Buenos Aires, Gastroenterol Sect, Hosp Jose M Penna, Buenos Aires, DF, Argentina
[4] Govt City Buenos Aires, Gastroenterol Sect, Consejo Invest, Buenos Aires, DF, Argentina
关键词
Hepatitis C; Liver fibrosis; Losartan; AT1R; Chronic liver disease; Angiotensin II;
D O I
10.3748/wjg.v11.i48.7560
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To evaluate the safety and efficacy of chronic administration of losartan on hepatic fibrosis in chronic hepatitis C patients. METHODS: Fourteen patients with chronic hepatitis C non-responders (n = 10), with contraindications (n = 2) or lack of compliance (n = 2) to interferon plus ribavirin therapy and liver fibrosis were enrolled. Liver and renal function test, clinical evaluation, and liver biopsies were performed at baseline and after losartan administration at a dose of 50 mg/d during the 6 mo. The control group composed of nine patients with the same inclusion criteria and paired liver biopsies (interval 6-14 mo). Histological activity index (HAI) with fi brosis stage was assessed under blind conditions by means of Ishak's score. Subendothelial fibrosis was evaluated by digital image analyses. RESULTS: The changes in the fibrosis stage were significantly different between losartan group (decrease of 0.5 +/- 1.3) and controls (increase of 0.89 +/- 1.27; P < 0.03). In the treated patients, a decrease in fi brosis stage was observed in 7/14 patients vs 1/9 control patients (P < 0.04). A decrease in sub-endothelial fi brosis was observed in the losartan group. No differences were found in HAI after losartan administration. Acute and chronic decreases in systolic arterial pressures (P < 0.05) were observed after the losartan administration, without changes in mean arterial pressure or renal function. CONCLUSION: Chronic AT-II type 1 receptor (AT1R) blockade may reduce liver fibrosis in patients with chronic hepatitis C. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
引用
收藏
页码:7560 / 7563
页数:4
相关论文
共 15 条
[1]   Evaluation of liver fibrosis: A concise review [J].
Afdhal, NH ;
Nunes, D .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (06) :1160-1174
[2]  
[Anonymous], 2002, NIH CONSENS STATE SC, V19, P1
[3]   Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II [J].
Bataller, R ;
Sancho-Bru, P ;
Ginès, P ;
Lora, JM ;
Al-Garawi, A ;
Solé, M ;
Colmenero, J ;
Nicolás, JM ;
Jiménez, W ;
Weich, N ;
Gutiérrez-Ramos, JC ;
Arroyo, V ;
Rodés, J .
GASTROENTEROLOGY, 2003, 125 (01) :117-125
[4]   Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension [J].
Croquet, V ;
Moal, F ;
Veal, N ;
Wang, JH ;
Oberti, F ;
Roux, J ;
Vuillemin, E ;
Gallois, Y ;
Douay, O ;
Chappard, D ;
Calès, P .
JOURNAL OF HEPATOLOGY, 2002, 37 (06) :773-780
[5]   Portal pressure response to losartan compared with propranolol in patients with cirrhosis [J].
De, BK ;
Bandyopadhyay, K ;
Das, TK ;
Das, D ;
Biswas, PK ;
Majumdar, D ;
Mandal, SK ;
Ray, S ;
Dasgupta, S .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (06) :1371-1376
[6]   A new image analysis method for quantification of liver fibrosis [J].
Fernandez, A ;
Castano, G ;
Sookoian, S ;
Lemberg, A ;
Amante, M ;
Parisi, C ;
Perazzo, JC .
JOURNAL OF HEPATOLOGY, 2003, 38 :216-216
[7]   Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis [J].
Gustavo, C ;
Pedro, V ;
Bernardo, F ;
Silvia, S .
GASTROENTEROLOGY, 2002, 122 (05) :1544-1545
[8]   Expression and localization of AT1 receptors in hepatic Kupffer cells:: its potential role in regulating a fibrogenic response [J].
Leung, PS ;
Suen, PM ;
Ip, SP ;
Yip, CK ;
Chen, G ;
Lai, PBS .
REGULATORY PEPTIDES, 2003, 116 (1-3) :61-69
[9]   Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis [J].
Schneider, AW ;
Kalk, JF ;
Klein, CP .
HEPATOLOGY, 1999, 29 (02) :334-339
[10]   A 1166C angiotensin II type I receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension [J].
Sookoian, S ;
Castaño, G ;
García, SI ;
Viudez, P ;
González, C ;
Pirola, CJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (03) :636-642